<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02711969</url>
  </required_header>
  <id_info>
    <org_study_id>BK-AM-GC102</org_study_id>
    <nct_id>NCT02711969</nct_id>
  </id_info>
  <brief_title>A Study of Apatinib Mesylate (YN968D1) 1,000mg in Gastric Cancer Patient Failed to Standard Treatment</brief_title>
  <official_title>A PhaseⅠStudy of Apatinib Mesylate (YN968D1) 1,000mg in Patients With Unresectable Locally Advanced or Metastatic Gastric Cancer Failed to Standard Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bukwang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bukwang Pharmaceutical</source>
  <brief_summary>
    <textblock>
      An open study to evaluate the safety of apatinib mesylate (YN968D1) 1,000mg monotherapy in
      patients with unresectable locally advanced or metastatic Gastric cancer failed to standard
      therapy.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2016</start_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-limiting toxicities (DLTs) of Apatinib mesylate in patients with unresectable locally advanced or metastatic gastric cancer</measure>
    <time_frame>First 28 days of dosing</time_frame>
    <description>Graded and described using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v 4.03</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse events (AEs), Serious AEs (SAEs), clinical laboratory abnormalities, and ECG abnormalities</measure>
    <time_frame>From date of registration to time of first progressive disease(PD) or death, an average of 1 year</time_frame>
    <description>Incidence and severity of treatment-related adverse events reported and their relationship to Apatinib mesylate will be assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.3)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response(Stable disease, partial response or Complete response)</measure>
    <time_frame>From date of registration to time of first progressive disease(PD) or death, an average of 1 year</time_frame>
    <description>Tumor response and progression will be evaluated using RECIST v 1.1.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">6</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>Apatinib mesylate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatinib mesylate</intervention_name>
    <description>1,000mg Apatinib mesylate p.o. qd</description>
    <arm_group_label>Apatinib mesylate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  19 years of age or older

          -  Subjects with histologically confirmed unresectable locally advanced or metastatic
             adenocarcinoma of the stomach or gastroesophageal junction

          -  Failure or noncompliance of existing standard treatment without alternative treatment

          -  Measurable disease measured by proper image examination defined by RECIST 1.1

          -  Life expectancy ≥ 3 months

          -  Subject must be suitable for oral administration of study medication

          -  Subject who can submit a written consent form before participating in the test

          -  Adequate bone marrow, renal, and liver function

          -  Electrocorticography(ECOG) performance status ≤ 2

          -  Ability and willingness to comply with the study protocol for the duration of the
             study

        Exclusion Criteria:

          -  Pregnant or lactating women

          -  Therapy with clinically significant systemic anticoagulant or antithrombotic agents
             within 7 days prior to first scheduled dose of YN968D1

          -  Hemoptysis within 3 months prior to first scheduled dose of YN968D1

          -  Cytotoxic chemotherapy, immunotherapy, radiotherapy or other targeted therapies within
             4 weeks (6 weeks in cases of mitomycin C, nitrosourea, lomustine) prior to first
             scheduled dose of YN968D1

          -  Surgery or biopsy within 28 days prior to first scheduled dose of YN968D1

          -  Minor surgery within 7 days prior to first scheduled dose of YN968D1

          -  Patients who have experience using YN968D1 before

          -  Concomitant treatment with strong inhibitors or inducers of CYP3A4, CYP2C9 and CYP2C19

          -  Known history of human immunodeficiency virus infection (HIV)

          -  Medical history of other cancers (including blood cancer) in the 5 years

          -  Radiology therapy to target lesion within 28 days, or diagnosis of other cancer within
             14 days prior to first scheduled dose of YN968D1

          -  History of bleeding diathesis or bleeding within 14 days prior to enrollment

          -  Medical history of clinically significant thrombosis (bleeding or clotting disorder)
             within the past 3-months

          -  History of non-malignant GI bleeding, gastric stress ulcerations, or peptic ulcer
             disease within the past 3-months

          -  History of idiopathic or hereditary angioedema, sickle cell or any hemolytic anemia

          -  History of uncontrolled hypertension that in the opinion of the investigator

          -  Complete Left bundle branch block (LBBB) or bifascicular (RBBB and left anterior or
             posterior hemi-block)

          -  Clinically significant S-T segment or T wave abnormality

          -  Abnormal atrial fibrillation

          -  History of ECOG or left ventricular ejection fraction (LVEF) abnormality during last 3
             months in the opinion of the investigator

          -  Myocardial infarction or unstable angina pectoris within 6 months prior to starting
             study medication

          -  Congestive heart failure (New York Heart Association class III-IV)

          -  History of other significant cardiovascular disease or vascular disease within the
             last 6 months

          -  History of clinically significant glomerulonephritis, biopsy proven tubulointerstitial
             nephritis, crystal nephropathy, or other renal insufficiencies Treatment with an
             investigational agent within the longest time frame of either 5 half-lives or 30 days
             of initiating study drug

          -  Half-life of other investigator drug is not passed over fivefold or 30 days prior to
             clinical trial

          -  Known recreational substance use or psychiatric illness that, in the opinion of the
             Investigator, may affect compliance with scheduled visits

          -  Known hypersensitivity to YN968D1 or components of the formulation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yoon-Koo Kang, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul Asan Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yoon-Koo Kang, PhD</last_name>
    <phone>82-2-3010-3230</phone>
    <email>ykkang@amc.seoul.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Asan medical center</name>
      <address>
        <city>Seoul</city>
        <state>Songpa-gu</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yoon Koo Kang, M.D., Ph.D.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 26, 2016</study_first_submitted>
  <study_first_submitted_qc>March 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2016</study_first_posted>
  <last_update_submitted>January 30, 2017</last_update_submitted>
  <last_update_submitted_qc>January 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

